These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1994996)

  • 21. Neonatal maple syrup urine disease case report and literature review.
    Liu Q; Li F; Zhou J; Liu X; Peng J; Gong L
    Medicine (Baltimore); 2022 Dec; 101(50):e32174. PubMed ID: 36550798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classical maple syrup urine disease: cofactor resistance.
    Elsas LJ; Pask BA; Wheeler FB; Perl DP; Truster S
    Metabolism; 1972 Oct; 21(10):929-44. PubMed ID: 4342010
    [No Abstract]   [Full Text] [Related]  

  • 23. Intermittent maple syrup disease.
    Bodamer OA; Leonard JV; Halliday D
    Lancet; 1996 Jan; 347(8995):191-2. PubMed ID: 8544561
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of insulin on leucine kinetics in maple syrup urine disease.
    Collins JE; Umpleby AM; Boroujerdi MA; Leonard JV; Sonksen PH
    Pediatr Res; 1987 Jan; 21(1):10-3. PubMed ID: 3540829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mild variant of maple syrup urine disease.
    Kovács J; Kiss P
    Acta Paediatr Acad Sci Hung; 1978; 19(2):137-43. PubMed ID: 707084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [3 patients with maple syrup urine disease].
    Merinero B; del Valle JA; García MJ; García Miguel MJ; Barrio MI; García Hortelano J; Morales E; González F; García Aparicio J; Sáez Pérez E
    An Esp Pediatr; 1983 Nov; 19(5):393-400. PubMed ID: 6660657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Compliance of the diet restricted with leucine, isoleucine and valine in maple syrup urine disease (MSUD) children].
    Kowalik A; Narojek L; Sykut-Cegielska J
    Rocz Panstw Zakl Hig; 2007; 58(1):95-101. PubMed ID: 17711097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of maple syrup disease. Clinical and electroencephalographic observations with dietetic experiment. Critical review of literature].
    Grossi-Bianchi ML; Gatti R; Marchi AG
    Minerva Pediatr; 1967 Aug; 19(33):1552-65. PubMed ID: 4889027
    [No Abstract]   [Full Text] [Related]  

  • 29. Alloisoleucine formation in maple syrup urine disease: isotopic evidence for the mechanism.
    Matthews DE; Ben-Galim E; Haymond MW; Bier DM
    Pediatr Res; 1980 Jul; 14(7):854-7. PubMed ID: 7413299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maple syrup urine disease variant: report on an infant.
    Koepp P; Rybak C; Rüdiger HW; Wendel U
    Z Kinderheilkd; 1974 Feb; 116(3):177-84. PubMed ID: 4813457
    [No Abstract]   [Full Text] [Related]  

  • 31. Interrelation between the metabolism of L-isoleucine and L-allo-isoleucine in patients with maple syrup urine disease.
    Wendel U; Langenbeck U; Seakins JW
    Pediatr Res; 1989 Jan; 25(1):11-4. PubMed ID: 2919111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maple syrup urine disease: two different forms within a single family.
    Frézal J; Amédée-Manesme O; Mitchell G; Heuertz S; Rey F; Rey J; Saudubray JM
    Hum Genet; 1985; 71(1):89-91. PubMed ID: 4029957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age dependence of diffusion-weighted magnetic resonance imaging findings in maple syrup urine disease encephalopathy.
    Sakai M; Inoue Y; Oba H; Ishiguro A; Sekiguchi K; Tsukune Y; Mitomo M; Nakamura H
    J Comput Assist Tomogr; 2005; 29(4):524-7. PubMed ID: 16012312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of DNA damage by L-carnitine induced by metabolites accumulated in maple syrup urine disease in human peripheral leukocytes in vitro.
    Mescka CP; Wayhs CA; Guerreiro G; Manfredini V; Dutra-Filho CS; Vargas CR
    Gene; 2014 Sep; 548(2):294-8. PubMed ID: 25046137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy.
    Felber SR; Sperl W; Chemelli A; Murr C; Wendel U
    Ann Neurol; 1993 Apr; 33(4):396-401. PubMed ID: 8489211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valine-toxic intermittent maple syrup urine disease: a previously unrecognized variant.
    Zipf WB; Hieber VC; Allen RJ
    Pediatrics; 1979 Feb; 63(2):286-94. PubMed ID: 440821
    [No Abstract]   [Full Text] [Related]  

  • 37. Metabolism of [1-(14)C] and [2-(14)C] leucine in cultured skin fibroblasts from patients with isovaleric acidemia. Characterization of metabolic defects.
    Tanaka K; Mandell R; Shih VE
    J Clin Invest; 1976 Jul; 58(1):164-72. PubMed ID: 932204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new variety of maple syrup urine disease.
    Harkness RA; Cockburn F; Grant M; Giles MM; Turner TL; Darling JA
    Ann Clin Biochem; 1977 May; 14(3):146-8. PubMed ID: 869494
    [No Abstract]   [Full Text] [Related]  

  • 39. An early diagnosis leads to a good prognosis: a patient with maple syrup urine disease--screened by tandem mass spectrometry.
    Lin JF; Chiu PC; Hsu HY; Lin SM; Chen YY; Hsieh KS
    Acta Paediatr Taiwan; 2004; 45(5):287-9. PubMed ID: 15868812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neuropathology of the maple syrup disease].
    Dambska M
    Neuropatol Pol; 1970; 8(4):349-55. PubMed ID: 5538195
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.